肝癌研究的变迁与趋势

汤钊猷

doi:10.3969/j.issn.1001-5256.2014.03.001

肝癌研究的变迁与趋势

DOI: 10.3969/j.issn.1001-5256.2014.03.001

汤钊猷

复旦大学附属中山医院肝癌研究所

详细信息

中图分类号: R735.7
计量
- 文章访问数: 2490
- HTML全文浏览量: 7
- PDF下载量: 790
- 被引次数: 0
出版历程
- 出版日期: 2014-03-20

Studies on liver cancer: evolution and perspectives

Tang ZhaoYou

摘要

摘要:
半个世纪以来肝癌研究发生了很大变迁,概述了主要变迁和今后趋势。（1）肝癌高危险因素已变为HBV与HCV感染、环境因素、生活方式、代谢内分泌和遗传因素,由此须调整预防措施。（2）美国、意大利和作者单位资料表明,肝癌预后的改善主要由于早诊早治,并继续成为提高疗效的重要途径。（3）保守治疗格局在变,分子靶向治疗是一个趋势。"杀癌+杀癌"的联合治疗仍有发展空间,而"杀癌+改造"的模式更值得关注。（4）癌转移观念已有更新,如转移乃全身性问题,转移不是晚期现象,免疫炎症微环境影响转移,转移主要与肿瘤干细胞有关,转移潜能可双向变。为此应重视全身性干预,包括神经、免疫、内分泌、代谢等;关注肿瘤干细胞的"改邪归正";关注抗炎剂的应用;关注中医中药。（5）杀癌疗法负面问题的干预是提高现有疗法疗效的一条捷径。"变"是绝对的,"不变"是相对的,站得高一点,看的远一点,有助推动事物发展。
- 肝肿瘤 /
- 危险因素 /
- 早期诊断 /
- 肿瘤转移 /
- 述评
Abstract:
Great changes have taken place in the studies on liver cancer over the past 50 years. The main evolution and perspectives are reviewed as follows: ( 1) Infections with hepatitis B virus and hepatitis C virus, environmental factors, lifestyle, and metabolic, endocrine, and hereditary factors have become the high- risk factors for liver cancer, so the preventive measures should be adjusted. ( 2) The research data from the USA, Italy, and the author's institute showed that early diagnosis and early treatment are the main contributors to improved prognosis of liver cancer, and they remain the important means for improving treatment outcome. ( 3) Conservative therapy is being transformed, and molecular targeted therapy is a direction in the future; “tumor- killing + tumor- killing”combination therapy still holds promise for application, while“tumor- killing + rehabilitation”modality is worth more attention. ( 4) The concept of cancer metastasis has been updated: metastasis is a systemic problem; metastasis is not a phenomenon in the advanced stage; the microenvironment of immune inflammation is an important factor for cancer metastasis; cancer metastasis is mainly related to tumor stem cells; the metastatic potential of cancer can be increased or decreased. Therefore, we should pay attention to the systemic intervention involving the nervous, immune, endocrine, and metabolic systems, tumor stem cells' “return to the right way”, the application of anti- inflammatory agent, and traditional Chinese medicine. ( 5) Intervention of the adverse effects of tumor- killing therapy is an easy way to improve treatment outcome. “Evolution”is absolute, while“constancy”is relative. We should be far- sighted to promote the treatment of liver cancer.
- liver neoplasms /
- risk factors /
- early diagnosis /
- neoplasms metastasis /
- editorial

HTML全文

参考文献(43)

[1]CLIFFORD RJ, ZHANG J, MEERZAMAN DM, et al.Genetic variations at loci involved in the immune response are risk factors for hepatocellular carcinoma[J].Hepatology, 2010, 52 (6) :2034-2043.

[2]HOSAKA T, SUZUKI F, KOBAYASHI M, et al.Long-term entecavir treatment reduces hepatocellular carcinoma incidence in patients with hepatitis B virus infection[J].Hepatology, 2013, 58 (1) :98-107.

[3]OGAWA E, FURUSYO N, KAJIWARA E, et al.Efficacy of pegylated interferon alpha-2b and ribavirin treatment on the risk of hepatocellular carcinoma in patients with chronic hepatitis C:a prospective, multicenter study[J].J Hepatol, 2013, 58 (3) :495-501.

[4]ROHR-UDILOVA N, SIEGHART W, EFERL R, et al.Antagonistic effects of selenium and lipid peroxides on growth control in early hepatocellular carcinoma[J].Hepatology, 2012, 55 (4) :1112-1121.

[5]ALTEKRUSE SF, MCGLYNN KA, DICKIE LA, et al.Hepatocellular carcinoma confirmation, treatment, and survival in surveillance, epidemiology, and end results registries, 1992-2008[J].Hepatology, 2012, 55 (2) :476-482.

[6]SANTI V, BUCCIONE D, DI MICOLI A, et al.The changing scenario of hepatocellular carcinoma over the last two decades in Italy[J].J Hepatol, 2012, 56 (2) :397-405.

[7]GIANNINI EG, FARINATI F, TREVISANI F.Alpha-fetoprotein in hepatocellular carcinoma surveillance:wake not the dead[J].Hepatology, 2011, 54 (1) :376-377.

[8]SHANG S, PLYMOTH A, GE S, et al.Identification of osteopontin as a novel marker for early hepatocellular carcinoma[J].Hepatology, 2012, 55 (2) :483-490.

[9]POMPILI M, SAVIANO A, de MATTHAEIS N, et al.Long-term effectiveness of resection and radiofrequency ablation for single hepatocellular carcinoma≤3 cm.Results of a multicenter Italian survey[J].J Hepatol, 2013, 59 (1) :89-97.

[10]KIM YS, LIM HK, RHIM H, et al.Ten-year outcomes of percutaneous radiofrequency ablation as first-line therapy of early hepatocellular carcinoma:analysis of prognostic factors[J].J Hepatol, 2013, 58 (1) :89-97.

[11]KOMATSU S, FUKUMOTO T, DEMIZU Y, et al.Clinical results and risk factors of proton and carbon ion therapy for hepatocellular carcinoma[J].Cancer, 2011, 117 (21) :4890-4904.

[12]ASGHAR U, MEYER T.Are there opportunities for chemotherapy in the treatment of hepatocellular cancer?[J]J Hepatol, 2012, 56 (3) :686-695.

[13]IAVARONE M, CABIBBO G, PISCAGLIA F, et al.Field-practice study of sorafenib therapy for hepatocellular carcinoma:a prospective multicenter study in Italy[J].Hepatology, 2011, 54 (6) :2055-2063.

[14]LACHENMAYER A, TOFFANIN S, CABELLOS L, et al.Combination therapy for hepatocellular carcinoma:additive preclinical efficacy of the HDAC inhibitor panobinostat with sorafenib[J].J Hepatol, 2012, 56 (6) :1343-1350.

[15]ZAANAN A, WILLIET N, HEBBAR M, et al.Gemcitabine plus oxaliplatin in advanced hepatocellular carcinoma:a large multicenter AGEO study[J].J Hepatol, 2013, 58 (1) :81-88.

[16]HSU YC, HO HJ, WU MS, et al.Postoperative peg-interferon plus ribavirin is associated with reduced recurrence of hepatitis C virus-related hepatocellular carcinoma[J].Hepatology, 2013, 58 (1) :150-157.

[17]UCHINO K, TATEISHI R, SHIINA S, et al.Hepatocellular carcinoma with extrahepatic metastasis:clinical features and prognostic factors[J].Cancer, 2011, 117 (19) :4475-4483.

[18]YE QH, QIN LX, FORGUES M, et al.Predicting hepatitis B virus-positive metastatic hepatocellular carcinomas using gene expression profiling and supervised machine learning[J].Nat Med, 2003, 9 (4) :416-423.

[19]BUDHU A, FORGUES M, YE QH, et al.Prediction of venous metastases, recurrence, and prognosis in hepatocellular carcinoma based on a unique immune response signature of the liver microenvironment[J].Cancer Cell, 2006, 10 (2) :99-111.

[20]KIM H, CHOI GH, NA DC, et al.Human hepatocellular carcinomas with“Stemness”-related marker expression:keratin 19 expression and a poor prognosis[J].Hepatology, 2011, 54 (5) :1707-1717.

[21]ZHAO Y, WANG X, WANG T, et al.Acetylcholinesterase, a key prognostic predictor for hepatocellular carcinoma, suppresses cell growth and induces chemosensitization[J].Hepatology, 2011, 53 (2) :493-503.

[22]ZHANG CH, XU GL, JIA WD, et al.Prognostic significance of osteopontin in hepatocellular carcinoma:a meta-analysis[J].Int J Cancer, 2012, 130 (11) :2685-2692.

[23]REN N, WU JC, DONG QZ, et al.Association of specific genotypes in metastatic suppressor HTPAP with tumor metastasis and clinical prognosis in hepatocellular carcinoma[J].Cancer Res, 2011, 71 (9) :3278-3286.

[24]ZHOU H, HUANG H, SHI J, et al.Prognostic value of interleukin 2and interleukin 15 in peritumoral hepatic tissues for patients with hepatitis B-related hepatocellular carcinoma after curative resection[J].Gut, 2010, 59 (12) :1699-1708.

[25]VILLANUEVA A, HOSHIDA Y, BATTISTON C, et al.Combining clinical, pathology, and gene expression data to predict recurrence of hepatocellular carcinoma[J].Gastroenterology, 2011, 140 (5) :1501-1512.

[26]MOTOMURA T, SHIRABE K, MANO Y, et al.Neutrophil-lymphocyte ratio reflects hepatocellular carcinoma recurrence after liver transplantation via inflammatory microenvironment[J].J Hepatol, 2013, 58 (1) :58-64.

[27]ONDICOVA K, MRAVEC B.Role of nervous system in cancer aetiopathogenesis[J].Lancet Oncol, 2010, 11 (6) :596-601.

[28]SPRINZL MF, GALLE PR.Facing the dawn of immunotherapy for hepatocellular carcinoma[J].J Hepatol, 2013, 59 (1) :9-10.

[29]LIAO CH, YEH CT, HUANG YH, et al.Dickkopf 4 positively regulated by the thyroid hormone receptor suppresses cell invasion in human hepatoma cells[J].Hepatology, 2012, 55 (3) :910-920.

[30]ISRAELSEN WJ, VANDER HEIDEN MG.ATP consumption promotes cancer metabolism[J].Cell, 2010, 143 (5) :669-671.

[31]NIEMAN KM, KENNY HA, PENICKA CV, et al.Adipocytes promote ovarian cancer metastasis and provide energy for rapid tumor growth[J].Nat Med, 2011, 17 (11) :1498-1503.

[32]YANG TS, LU SN, CHAO Y, et al.A randomised phase II study of pegylated arginine deiminase (ADI-PEG 20) in Asian advanced hepatocellular carcinoma patients[J].Br J Cancer, 2010, 103 (7) :954-960.

[33]GARCIA-CAO I, SONG MS, HOBBS RM, et al.Systemic elevation of PTEN induces a tumor-suppressive metabolic state[J].Cell, 2012, 149 (1) :49-62.

[34]DINARELLO CA.Anti-inflammatory agents:present and future[J].Cell, 2010, 140 (6) :935-950.

[35]JIA QA, REN ZG, BU Y, et al.Herbal compound“Songyou Yin”renders hepatocellular carcinoma sensitive to oxaliplatin through inhibition of stemness[J].Evid Based Complement Altern Med, 2012, 2012:908601.

[36]JIA QA, WANG ZM, REN ZG, et al.Herbal compound“Songyou Yin”attenuates hepatoma cell invasiveness and metastasis through downregulation of cytokines secreted by activated hepatic stellate cells[J].BMC Complement Altern Med, 2013, 13:89.

[37]Willyard C.Lifestyle:Breaking the cancer habit[J].Nature, 2011, 471 (7339) :s16-17.

[38]HUANG XY, HUANG ZL, WANG L, et al.Herbal compound“Songyou Yin”reinforced the ability of interferon-alfa to inhibit the enhanced metastatic potential induced by palliative resection of hepatocellular carcinoma in nude mice[J].BMC Cancer, 2010, 10:580.

[39]JIA JB, WANG WQ, SUN HC, et al.A novel tripeptide, tyroserleutide, inhibits irradiation-induced invasiveness and metastasis of hepatocellular carcinoma in nude mice[J].Invest New Drugs, 2011, 29 (5) :861-872.

[40]XIONG W, REN ZG, QIU SJ, et al.Residual hepatocellular carcinoma after oxaliplatin treatment has increased metastatic potential in a nude mouse model and is attenuated by Songyou Yin[J].BMC Cancer, 2010, 10:219.

[41]ZHANG W, SUN HC, WANG WQ, et al.Sorafenib down-regulates expression of HTATIP2 to promote invasiveness and metastasis of orthotopic hepatocellular carcinoma tumors in mice[J].Gastroenterology, 2012, 143 (6) :1641-1649.

[42]ZHANG QB, SUN HC, ZHANG KZ, et al.Suppression of natural killer cells by sorafenib contributes to prometastatic effects in hepatocellular carcinoma[J].PLoS One, 2013, 8 (2) :e55945.

[43]LU L, SUN HC, ZHANG W, et al.Aspirin minimized the prometastasis effect of sorafenib and improved survival by up-regulating HTATIP2 in hepatocellular carcinoma[J].PLoS One, 2013, 8 (5) :e65023.

施引文献

资源附件(0)

访问统计